Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Phase 3 Trial to Evaluate the Safety of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa (PA) in the Lower Airways

NCT01404234 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01404234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01404234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Phase 3 Trial to Evaluate the Safety of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa (PA) in the Lower Airways
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2011
Completion date
April 30, 2013
Enrollment
61 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis, pseudomonas aeruginosa